Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6296-6304

  Eskens, Ferry A L M ^a   Ramos, Francisco J ^b   Burger, Herman ^a   O'Brien, James P ^c   Piera, Adelaida ^b   De Jonge, Maja J A ^a   Mizui, Yoshiharu ^d   Wiemer, Erik A C ^a   Carreras, Maria Josepa ^b   Baselga, Jose ^e   Tabernero, Josep ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c EISAI INC   (United States)

^d EISAI CO LTD   (Japan)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; E 7107; INITIATION FACTOR 4A; MESSENGER RNA; SPLICEOSOME INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; BLURRED VISION; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE TARGETING; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; LIMIT OF QUANTITATION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RNA SPLICING; SOLID TUMOR; SPLICEOSOME; STOMACH CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UTERUS CANCER; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DRUG ADMINISTRATION SCHEDULE; EPOXY COMPOUNDS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; M PHASE CELL CYCLE CHECKPOINTS; MACROLIDES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RNA, MESSENGER; SPLICEOSOMES; TREATMENT OUTCOME;

EID: 84888100819     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0485     Document Type: Article

References (18)

1. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, et al. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J Antibiot 2004;57:188-96. (Pubitemid 38489677)
2. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007;3:570-5. (Pubitemid 47294394)
3. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007;3:576-83. (Pubitemid 47294395)
4. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009;100:228-32.
5. Körner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol 2009;175:461-72.
6. Miura K, Fujibuchi W, Sasaki I. Alternative pre-mRNA splicing in digestive tract malignancy. Cancer Sci 2011;102:309-16.
7. Folco EG, Coil KE, Reed R. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 2011;25:440-4.
8. Iwata M, Ozawa Y, Uenaka T, Shimizu H, Niijima J, Kanada RM, et al. E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts [abstract 2989]. Proc Am Assoc Cancer Res 2004;45:691.
9. Niijima J, Kotake Y, Kanada RM, Nagai M, Fukuda Y, Sakai T, et al. E7107, a new 7-urethane derivative of pladienolide D: Discovery of a novel antitumor agent [abstract 2988]. Proc Am Assoc Cancer Res 2004;45:691.
10. Uenaka T, Iwata M, Ozawa Y, Shimizu H, Kotake Y, Mizui Y, et al. E7107, a new 7-urethane derivative of pladienolide D: correlation of the profile of cell cycle regulatory molecules with tumor cells' response [abstract 2991]. Proc Am Assoc Cancer Res 2004;45:691.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Burger H, Foekens JA, Look MP, Meije-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-36. (Pubitemid 36182621)
13. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-72.
14. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-95.
15. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012;26:542-5.
16. Damm F, Thol F, Kosmider O, Kade S, Löffeld P, Dreyfus F, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012;26:1137-40.
17. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506.
18. O'Brien K, Matlin AJ, Lowell AM, Moore MJ. The biflavonoid isoginkgetin is a general inhibitor of pre-mRNA splicing. J Biol Chem 2008;283:33147-54.